[關(guān)鍵詞]
[摘要]
白術(shù)Atractylodis Macrocephalae Rhizoma-白芍Paeoniae Radix Alba為臨床常用藥對(duì),二藥配伍后相使而行,善于調(diào)和肝脾。以白術(shù)-白芍為核心或組成部分的方劑,其功效在不同的方劑配伍情境下存在差異。白術(shù)-白芍富含多種化學(xué)成分,因炮制方法、藥物配比、檢測(cè)條件等因素不同,其主要成分白術(shù)內(nèi)酯、芍藥苷、芍藥內(nèi)酯苷等經(jīng)配伍、炮制后含量也有所變化。白術(shù)-白芍治療疾病機(jī)制聚焦于胃腸功能調(diào)節(jié)、抗炎、調(diào)節(jié)免疫及神經(jīng)保護(hù)方面。通過(guò)對(duì)相關(guān)文獻(xiàn)的檢索與整理,主要從復(fù)方配伍、物質(zhì)基礎(chǔ)及作用機(jī)制方面對(duì)白術(shù)-白芍藥對(duì)進(jìn)行系統(tǒng)論述,為該藥對(duì)的深入研究及開(kāi)發(fā)應(yīng)用提供思路和科學(xué)依據(jù)。
[Key word]
[Abstract]
Baizhu (Atractylodis Macrocephalae Rhizoma)-Baishao (Paeoniae Radix Alba) is commonly used clinical drug pairs. After the two drugs are combined, they work together and are good at harmonizing the liver and spleen. The efficacy of prescriptions with Atractylodis Macrocephalae Rhizoma-Paeoniae Radix Alba as the core or component varies in different prescription compatibility situations. Atractylodis Macrocephalae Rhizoma-Paeoniae Radix Alba are rich in a variety of chemical components. Due to different processing methods, drug ratios, detection conditions and other factors, the content of its main components, such as atractylenolide, paeoniflorin, and paeoniflorin, also changes after compatibility and processing. The mechanism of Atractylodis Macrocephalae Rhizoma-Paeoniae Radix Alba in treating diseases focuses on gastrointestinal function regulation, anti-inflammation, immune regulation and neuroprotection. This study systematically discusses Atractylodis Macrocephalae Rhizoma-Paeoniae Radix Alba pair from the aspects of compound compatibility, material basis and mechanism of action through the retrieval and collation of relevant literature, in order to provide ideas and scientific basis for the in-depth research and development and application of this drug pair.
[中圖分類號(hào)]
R285
[基金項(xiàng)目]
國(guó)家自然科學(xué)基金面上項(xiàng)目(81573870);國(guó)家中醫(yī)藥管理局第五批全國(guó)中醫(yī)臨床優(yōu)秀人才研修項(xiàng)目(國(guó)中醫(yī)藥人教函 [2022] 239號(hào));第五批全國(guó)中醫(yī)臨床優(yōu)秀人才研修項(xiàng)目(國(guó)中醫(yī)藥人教函[2022] 1號(hào));全國(guó)中醫(yī)藥創(chuàng)新骨干人才培養(yǎng)項(xiàng)目(國(guó)中醫(yī)藥人教函[2019] 128號(hào))